Difference between revisions of "Team:NCTU Formosa"

 
(24 intermediate revisions by 6 users not shown)
Line 28: Line 28:
 
         .div2{
 
         .div2{
 
         background:#fff;
 
         background:#fff;
height:90vh;
+
height:100vh;
 
         width:100%;
 
         width:100%;
 
         position:relative;
 
         position:relative;
Line 42: Line 42:
 
.div3-1{
 
.div3-1{
 
         background:#fff;
 
         background:#fff;
         width:28vw;
+
         width:28%;
height:28vw;
+
height:18vw;
 
         position:absolute;
 
         position:absolute;
 
         left:8%;
 
         left:8%;
Line 51: Line 51:
 
         .div3-2{
 
         .div3-2{
 
         background:#fff;
 
         background:#fff;
         width:28vw;
+
         width:28%;
height:28vw;
+
height:18vw;
 
 
 
position:absolute;
 
position:absolute;
Line 61: Line 61:
 
         .div3-3{
 
         .div3-3{
 
         background:#fff;
 
         background:#fff;
         width:28vw;
+
         width:28%;
height:28vw;
+
height:18vw;
 
 
 
position:absolute;
 
position:absolute;
Line 82: Line 82:
 
         video#bgvid{  
 
         video#bgvid{  
 
position:relative;
 
position:relative;
top:100px;
+
top:80px;
 
         min-width: 72%;
 
         min-width: 72%;
 
         min-height: 72%;
 
         min-height: 72%;
Line 188: Line 188:
 
<div class="div1">
 
<div class="div1">
 
<div class="div1-1">
 
<div class="div1-1">
<video autoplay id="bgvid">
+
<video autoplay id="bgvid" controls="true">
<source src="https://static.igem.org/mediawiki/2015/4/4a/Nctu_formosa_homepage_video2.mp4" type="video/mp4">
+
<source src="https://static.igem.org/mediawiki/2015/0/09/Nctu_formosa_homepage_vide5.mp4" type="video/mp4">
 
</source>
 
</source>
 
         </video>
 
         </video>
Line 197: Line 197:
 
     <div class="div2">
 
     <div class="div2">
 
<div class="p-2"></div>
 
<div class="p-2"></div>
         <div style="position:absolute;bottom:20%;width:100%;text-align:center;font-size:18pt;letter-spacing:5px;">The only thing we can detect is everything.</div>
+
         <div style="position:absolute;bottom:30%;width:100%;text-align:center;font-size:18pt;letter-spacing:5px;">The only thing we can detect is everything.</div>
 
</div>
 
</div>
 
      
 
      
Line 203: Line 203:
 
<div class="div3-1">
 
<div class="div3-1">
 
 
           <img src="https://static.igem.org/mediawiki/2015/5/51/2015_NCTU_Formosa_Homepage_21.png" align="center" height=200px>  
+
           <img src="https://static.igem.org/mediawiki/2015/5/51/2015_NCTU_Formosa_Homepage_21.png" align="center" height=250px>  
      <div class="photocontent1"><h2>Who are we</h2>
+
      <div class="photocontent1"><h2>Who we are</h2>
       NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO  
+
       NCTU_Formosa created an organization—APOllO, which stands for Almighty Probe of scFv Organization. APOllO is devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to create a brand new detection platform using synthetic biology.</div>
        devoted to developing detection technology by uti-  lizing antibodies. In 2015, We cooperated with iGEM with Synthetic 
+
        Biology to develop a brand new detection platform.</div>
+
 
    </div>
 
    </div>
 
              
 
              
 
         <div class="div3-2">
 
         <div class="div3-2">
    <img src="https://static.igem.org/mediawiki/2015/2/2e/NCTU_Formosa_Homepage_antibody.png" align="middle" height=200px>  
+
    <img src="https://static.igem.org/mediawiki/2015/2/2e/NCTU_Formosa_Homepage_antibody.png" align="middle" height=250px>  
 
      <div class="photocontent1"><h2>What's new</h2>
 
      <div class="photocontent1"><h2>What's new</h2>
 
  APOllO E.Cotector:<br>   
 
  APOllO E.Cotector:<br>   
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen -antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
+
Our organization creates a customized scFv detection platform by co-transforming any desired plasmid in to <i>E. coli</i>. ScFv utilizes antigen-antibody interaction to act as probes. Therefore, our E.Cotector has the function of a detector.
 
      </div> </div>
 
      </div> </div>
 
              
 
              
 
           <div class="div3-3">
 
           <div class="div3-3">
    <img src="https://static.igem.org/mediawiki/2015/2/2c/Nctu_formosa_homepage_cell.png" align="middle" height=200px>  
+
    <img src="https://static.igem.org/mediawiki/2015/7/77/Nctu_formosa_homepage_photo3.jpg" align="middle" height=250px>  
 
             
 
             
        <div class="photocontent1"><h2>What do we care</h2>
+
        <div class="photocontent1"><h2>What we care about</h2>
 
         
 
         
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.<br>
+
In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it. Therefore lowering the mortality rate of cancer. <br>
 
             </div>
 
             </div>
 
      </div>
 
      </div>

Latest revision as of 02:41, 19 September 2015

The only thing we can detect is everything.

Who we are

NCTU_Formosa created an organization—APOllO, which stands for Almighty Probe of scFv Organization. APOllO is devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to create a brand new detection platform using synthetic biology.

What's new

APOllO E.Cotector:
Our organization creates a customized scFv detection platform by co-transforming any desired plasmid in to E. coli. ScFv utilizes antigen-antibody interaction to act as probes. Therefore, our E.Cotector has the function of a detector.

What we care about

In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it. Therefore lowering the mortality rate of cancer.